Liquidia Corporation
LQDA
Rangering i aksjer
#4669
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Aksjekurs
$36.17
Sist synkronisert: 2026-10-20
Markedsverdi
$3.24B
Endring (1 dag)
5.98%
Endring (1 år)
53.33%
Land
US
Handel Liquidia Corporation (LQDA)
Kategori
Healthcare
Historikk for aksjesplitt for Liquidia Corporation (LQDA)
Aksjen Liquidia Corporation (symbol: LQDA) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én LQDA-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 LQDA-aksjer.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én LQDA-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 LQDA-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 0 | - |
US
|
|
| 0 | - |
SE
|
|
| 0 | - |
FR
|
|
| 0 | - |
IT
|
|
| 0 | - |
US
|
